Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy

Abstract

Background: Chromothripsis caused massive, clustered genomic rearrangements is prevalent in cancer and is considered a new paradigm for tumorigenesis and progression. In this study, we investigated the association among chromothripsis, anti-tumor immune responses, and responsiveness to immune checkpoint blockade (ICB). Methods: Quantification of immune cell infiltration and functional enrichment of immune-related signaling pathways were performed in the discovery set (n = 9403) and the validation set (n = 1140). we investigated the association between chromothripsis and anti-tumor immune responses. In the immunotherapy cohort, copy number alteration-based chromothripsis scores (CPSs) were introduced to assess the extent of chromothripsis to evaluate its association with responsiveness to ICB. Results: In the discovery set and the validation set, the ratios of CD8 + T cells to Tregs, TAMs, and MDSCs were significantly lower in tumors with chromothripsis (P = 1.5 × 10 − 13 , P = 5.4 × 10 − 8 , and P = 1.2 × 10 − 4 , respectively, TCGA; P = 1.0 × 10 − 13 , P = 3.6 × 10 − 15 , and P = 3.3 × 10 − 3 , respectively, PCAWG). The relevant pathways underlying the antitumor immune effect were significantly enriched in tumors without chromothripsis. Chromothripsis can be used as an independent predictor, and patients with low-CPSs experienced longer overall survival (OS) after immunotherapy [HR, 1.90; 95% confidence interval, 1.10−3.28; P = 0.019]. Conclusions: Our findings highlight the reduced cytotoxic immune infiltration in tumors with chromothripsis and enhanced immunosuppression in the tumor microenvironment. Chromothripsis can thus be used as a potential indicator to help identify patients who will respond to ICB, which could complement established biomarkers.

IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype

“…Thus, we aimed to characterize the immune context of the TME with GBP1 expression. It has been reported that the ratio of pro-inflammatory cytokines to immunosuppressive cytokines and the ratio of CD8 + T cells to Tregs, tumor-associated macrophages (TAMs), and MDSCs are related to the responsiveness to ICB immunotherapy [ 35 ]. Pro-inflammatory and immunosuppressive cytokines were significantly elevated in tumors with high GBP1 expression, which suggests that GBP1 could support anti-tumor immunity.…”